Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Resmed Inc (NY: RMD )

182.20 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 241
Open 182.20
Bid (Size) 185.50 (1)
Ask (Size) 188.49 (1)
Prev. Close 182.20
Today's Range 182.20 - 182.20
52wk Range 132.24 - 229.97
Shares Outstanding 146,234,244
Dividend Yield 1.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why ResMed Shares Are Trading Lower Monday
ResMed stock is trading lower Monday after Eli Lilly and Company released data from a clinical trial in regards to the treatment of sleep apnea. 
Via Benzinga
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
Via Benzinga

Performance

YTD
+6.07%
+6.07%
1 Month
-12.05%
-12.05%
3 Month
-5.75%
-5.75%
6 Month
+5.08%
+5.08%
1 Year
-15.05%
-15.05%

More News

Read More
Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday?
Via Benzinga
Topics Stocks
Exposures US Equities
(RMD) - Analyzing ResMed's Short Interest
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $11,000 Today
Via Benzinga
(RMD) - Analyzing ResMed's Short Interest
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Via Benzinga
Stocks Mixed As Investors Take Big Tech Profits
Via Talk Markets
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again
Via Investor's Business Daily
Nasdaq Futures Slip As Nvidia Sell-Off Continues, S&P 500 Futures Hold Up: Analyst Says 'Valuations Will Go Parabolic And It Will Be A Perfect Time To Sell'
Via Benzinga
Topics Stocks
Exposures US Equities
Elliott Wave Technical Forecast: Unlocking ASX Trading Success: ResMed Inc
Via Talk Markets
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
From ResMed Inc.
Via GlobeNewswire
(RMD) - Analyzing ResMed's Short Interest
Via Benzinga
Stryker Stock Sees RS Rating Treks Higher To 71
Via Investor's Business Daily
$100 Invested In ResMed 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
From ResMed Inc.
Via GlobeNewswire
Betting on Nvidia: 3 ETFs to Own for Exposure to the AI Giant
Via InvestorPlace
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Why ResMed Stock Is Soaring Today
Via The Motley Fool
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
From ResMed Inc.
Via GlobeNewswire
MatrixCare Joins Health Gorilla’s Qualified Health Information Network (QHIN) to Enhance Patient Data Access
From MatrixCare
Via GlobeNewswire
All-Time Highs In Sight: The Critical Signals You Can't Ignore
Via Talk Markets
Topics Stocks
Exposures US Equities
ResMed Announces Participation in the RBCCM Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
Top Research Reports For Apple, Linde & Comcast
Via Talk Markets
Inspire Medical Systems Stock Sees IBD RS Rating Rise To 78
Via Investor's Business Daily
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.